Pathology services company StrataDx has added Jim Agnello as Chief Financial Officer; Greg Richard as Executive Vice President of Sales & Marketing; and Steve Casper to its Board of Directors. The company is backed by Linden Capital Partners.
StrataDx, a leader in anatomic pathology services, announced the appointments of Jim Agnello as Chief Financial Officer, Greg Richard as Executive Vice President of Sales & Marketing, and Steve Casper to its Board of Directors. StrataDx provides clinicians with high-quality pathology services in the fields of dermatology, urology, podiatry, oral pathology, gastroenterology and gynecology.
Jim Agnello, CPA, joins StrataDx as the Chief Financial Officer and brings over two decades of financial and laboratory operational expertise. Mr. Agnello served as the Chief Financial Officer of Clarient and Nodality and most recently, as the Vice President of Operations for Healthtronics, Inc. He also spent 18 years with SmithKline Beecham in a variety of senior financial positions. Jim has a Master’s Degree in Accounting from the Wharton School at the University of Pennsylvania and a Bachelors Degree in Business Administration from Rutgers, the State University of New Jersey.
Greg Richard joins the company as the Executive Vice President of Sales & Marketing and brings extensive senior sales leadership expertise in not only the laboratory industry, but in Managed Care, Biotech, and Clinical Trials as well. Most recently, he was the Chief Commercial Officer at Signal Genetics, a specialty molecular testing Company, and served previously as the Sales Officer for LabCorp’s Northeast Division and the Vice President of Managed Care and Global Sales and Marketing for Clinical Trials at Quest Diagnostics. Greg received a B.A. from Westminster College.
Steven E. Casper has been named to the board of StrataDx. He is currently the Chief Executive Officer of National Dentex Corporation. Mr. Casper has significant experience developing successful health care organizations. Prior to National Dentex, Mr. Casper was involved in the founding and development of AmeriPath and Dermpath Diagnostics, both leading providers of pathology services. Mr. Casper served as the President of Dermpath Diagnostics, a division of Quest Diagnostics, Inc. and previously held senior executive roles at AmeriPath and Summit Partners. Steven received a B.A from Boston College.
“These appointments represent a significant milestone for StrataDx. Greg and Jim both have stellar track records of driving growth and generating value in their respective organizations.” said Pat Noland, Chief Executive Officer, StrataDx.
Richard Novak, Chairman of the StrataDx Board of Directors adds, “We are pleased to welcome Steven to the Board. His breadth of knowledge and expertise will contribute to the ongoing evolution of StrataDx as a best in class pathology services organization.”
StrataDx is a full service anatomic pathology laboratory that offers services in all areas of surgical pathology and cytology as well as molecular diagnostics and immunoflorescence. The pathology team is comprised of members with subspecialty board certification in dermatopathology, hematopathogy, cytopathology, nuclear medicine, clinical pathology, and the majority of the pathologists have more than two decades of medical experience. Many also have teaching appointments at some of the nation’s most prestigious academic medical centers including Harvard, Tufts, and the Univ. of Pennsylvania. StrataDx services customers ranging from major regional hospitals to small, independent physician practices in more than 40 states. Headquartered in Lexington, MA, with additional locations in Cambridge, MA, the company has more than 100 employees.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden’s strategy is comprised of three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic corporate relationships. Linden invests in middle market companies across the healthcare spectrum, including medical products, healthcare services, and distribution.